Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Bladder Cancer, July 2019

Free Subscription


Abstracts

Retrieve all available abstracts of the following 180 articles:
HTML format


 

Single Articles

  1. KATO D, Kawase M, Ishida T, Kato S, et al
    [Investigation of Clinical Outcome and Prognosis of 2nd TUR-Bt for T1 High Grade Bladder Cancer].
    Hinyokika Kiyo. 2019;65:105-109.
    Abstract    

    Abstract available

  2. HUA X, Huang M, Deng X, Xu J, et al
    The inhibitory effect of compound ChlA-F on human bladder cancer cell invasion can be attributed to its blockage of SOX2 protein.
    Cell Death Differ. 2019 Jun 26. pii: 10.1038/s41418-019-0377.
    Abstract    

    Abstract available

  3. RETZ M, von Amsberg G, Horn T, Gschwend JE, et al
    [50 years of systemic therapy of urinary bladder cancer].
    Aktuelle Urol. 2019 Jun 26. doi: 10.1055/a-0945-8340.
    Abstract    

    Abstract available

  4. XIA Y, Kang TW, Jung DY, Zhang C, et al
    Sulforaphane inhibits non-muscle invasive bladder cancer cells proliferation through suppression of HIF-1alpha-mediated glycolysis in hypoxia.
    J Agric Food Chem. 2019 Jun 26. doi: 10.1021/acs.jafc.9b03027.
    Abstract    

    Abstract available

  5. JIN H, Xue L, Mo L, Zhang D, et al
    Downregulation of miR-200c stabilizes XIAP mRNA and contributes to invasion and lung metastasis of bladder cancer.
    Cell Adh Migr. 2019;13:236-248.
    Abstract    

    Abstract available

  6. REBOLA J, Aguiar P, Blanca A, Montironi R, et al
    Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
    Virchows Arch. 2019 Jun 25. pii: 10.1007/s00428-019-02593.
    Abstract    

    Abstract available

  7. SCHULSTER M
    Bladder Cancer Academy 2019 Selected Summaries.
    Rev Urol. 2019;21:23-28.
    Abstract    



  8. SHI X, Chen S, Zhang Y, Xie W, et al
    Norcantharidin inhibits the DDR of bladder cancer stem-like cells through cdc6 degradation.
    Onco Targets Ther. 2019;12:4403-4413.
    Abstract    

    Abstract available

  9. SUNG JM, Martin JW, Jefferson FA, Sidhom DA, et al
    Racial and Socioeconomic Disparities in Bladder Cancer Survival: Analysis of the California Cancer Registry.
    Clin Genitourin Cancer. 2019 May 31. pii: S1558-7673(19)30146.
    Abstract    

    Abstract available

  10. ROUPRET M, Malmstrom PU, Black P
    Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options?
    Eur Urol Oncol. 2019 Jun 22. pii: S2588-9311(19)30078.
    Abstract    

    Abstract available

  11. MITCHELL KA, Williams H
    Emerging genomic biomarkers for improving kidney, prostate, and bladder cancer health disparities outcomes.
    Urol Oncol. 2019 Jun 22. pii: S1078-1439(19)30157.
    Abstract    

    Abstract available

  12. STOJNEV S, Krstic M, Cukuranovic Kokoris J, Conic I, et al
    Prognostic Impact of Canonical TGF-beta Signaling in Urothelial Bladder Cancer.
    Medicina (Kaunas). 2019;55.
    Abstract    

    Abstract available

  13. ABDEL-RAHMAN O
    Bladder cancer mortality after a diagnosis of nonmuscle-invasive bladder carcinoma.
    Future Oncol. 2019 Jun 25. doi: 10.2217/fon-2018-0861.
    Abstract    

    Abstract available

  14. SCHULPEN M, van den Brandt PA
    Adherence to the Mediterranean diet and risks of prostate and bladder cancer in the Netherlands Cohort Study.
    Cancer Epidemiol Biomarkers Prev. 2019 Jun 24. pii: 1055-9965.EPI-19-0224.
    Abstract    

    Abstract available

  15. HUANG CP, Chen J, Chen CC, Liu G, et al
    ASC-J9(R) increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-kappaB survival signals.
    J Exp Clin Cancer Res. 2019;38:275.
    Abstract    

    Abstract available

  16. HAYASHIDA Y, Miyata Y, Matsuo T, Ohba K, et al
    A pilot study to assess the safety and usefulness of combined transurethral endoscopic mucosal resection and en-bloc resection for non-muscle invasive bladder cancer.
    BMC Urol. 2019;19:56.
    Abstract    

    Abstract available

  17. JORDAHL KM, Phipps AI, Randolph TW, Tindle HA, et al
    Differential DNA methylation in blood as a mediator of the association between cigarette smoking and bladder cancer risk among postmenopausal women.
    Epigenetics. 2019 Jun 23:1-9. doi: 10.1080/15592294.2019.1631112.
    Abstract    

    Abstract available

  18. BLANCA A, Sanchez-Gonzalez A, Requena MJ, Carrasco-Valiente J, et al
    Expression of miR-100 and miR-138 as prognostic biomarkers in Non- Muscle Invasive Bladder Cancer.
    APMIS. 2019 Jun 24. doi: 10.1111/apm.12973.
    Abstract    

    Abstract available

  19. ZAHOOR H, Mir MC, Barata PC, Stephenson AJ, et al
    Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer.
    Invest New Drugs. 2019 Jun 24. pii: 10.1007/s10637-018-00716.
    Abstract    

    Abstract available

  20. HAN J, Wang JZ, Yang X, Yu H, et al
    METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner.
    Mol Cancer. 2019;18:110.
    Abstract    

    Abstract available

  21. LU Q, Liu T, Feng H, Yang R, et al
    Circular RNA circSLC8A1 acts as a sponge of miR-130b/miR-494 in suppressing bladder cancer progression via regulating PTEN.
    Mol Cancer. 2019;18:111.
    Abstract    

    Abstract available

  22. KRIMPHOVE MJ, Szymaniak J, Marchese M, Tully KH, et al
    Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy.
    Eur Urol Focus. 2019 Jun 18. pii: S2405-4569(19)30156.
    Abstract    

    Abstract available

  23. ROPERTO S, Russo V, De Falco F, Urraro C, et al
    Bovine papillomavirus E5 oncoprotein expression and its association with an interactor network in aggresome-autophagy pathway.
    Vet Microbiol. 2019;233:39-46.
    Abstract    

    Abstract available

  24. GHATE K, Amir E, Kuksis M, Hernandez-Barajas D, et al
    PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis.
    Cancer Treat Rev. 2019;76:51-56.
    Abstract    

    Abstract available

  25. KRISTYNA P, Tomas P, Ondrej H
    Current status of urine cytology: What new does The Paris System for Reporting Urine Cytology bring?
    Cesk Patol. 2019;55:34-41.
    Abstract    

    Abstract available

  26. MASSIE J, Howling S
    Schistosoma haematobium causing pulmonary schistosomiasis in a returning traveller.
    BMJ Case Rep. 2019;12.
    Abstract    

    Abstract available

  27. JAYAWARDHANA T, Alsayed H, Goel A, Madaan S, et al
    Non-muscle-invasive clear cell carcinoma of the urinary bladder: Is cystectomy necessary?
    BMJ Case Rep. 2019;12.
    Abstract    

    Abstract available

  28. HUANG C, Zhou W, Song P, Yuan N, et al
    Comparison of different prognostic models for predicting cancer-specific survival in bladder transitional cell carcinoma.
    Future Oncol. 2019;15:851-864.
    Abstract    

    Abstract available

  29. VURUSKAN BA, Ozsen M, Coskun B, Yalcinkaya U, et al
    Evaluation of incidence and histolopathological findings of soft tissue sarcomas in genitourinary tract: Uludag university experience.
    Int Braz J Urol. 2019;45:68-73.
    Abstract    

    Abstract available

  30. ZHANG G, Wang Q, Yang M, Yuan Q, et al
    OSblca: A Web Server for Investigating Prognostic Biomarkers of Bladder Cancer Patients.
    Front Oncol. 2019;9:466.
    Abstract    

    Abstract available

  31. KRAJEWSKI W, Rodriguez-Faba O, Breda A, Pisano F, et al
    The 1973 WHO and 2004 WHO grading systems are not equal in prediction of survival among stage T1 bladder cancer patients.
    Actas Urol Esp. 2019 Jul 2. pii: S0210-4806(19)30100.
    Abstract    

    Abstract available

  32. RICCARDI N, Ferrarese M, Castellotti P, Mazzola E, et al
    A rare case of multi-focal human TB after BCG instillation for non-muscle-invasive bladder cancer.
    Urologia. 2019 Jul 4:391560319860396. doi: 10.1177/0391560319860396.
    Abstract    

    Abstract available

  33. SEGOVIA C, San Jose-Eneriz E, Munera-Maravilla E, Martinez-Fernandez M, et al
    Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression.
    Nat Med. 2019 Jul 3. pii: 10.1038/s41591-019-0499.
    Abstract    

    Abstract available

  34. GAO BS, Rong CS, Xu HM, Sun T, et al
    Peptidyl Arginine Deiminase, Type II (PADI2) Is Involved in Urothelial Bladder Cancer.
    Pathol Oncol Res. 2019 Jul 2. pii: 10.1007/s12253-019-00687.
    Abstract    

    Abstract available

  35. SCHWAMBORN K, Ammann JU, Knuchel R, Hartmann A, et al
    Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
    Virchows Arch. 2019 Jul 2. pii: 10.1007/s00428-019-02610.
    Abstract    

    Abstract available

  36. FROEHNER M, Koch R, Heberling U, Hubler M, et al
    Which comorbidity classification is best suited to identify patients at risk for 90-day and long-term non-bladder cancer mortality after radical cystectomy?
    World J Urol. 2019 Jul 2. pii: 10.1007/s00345-019-02860.
    Abstract    

    Abstract available

  37. PEREIRA R, Perera M, Rhee H
    Metastatic plasmacytoid bladder cancer causing malignant priapism.
    BMJ Case Rep. 2019;12.
    Abstract    

    Abstract available

  38. LI Y, Zhang X, Zhou X, Zhang X, et al
    LHPP suppresses the bladder cancer cell proliferation and growth via inactivating AKT/p65 signaling pathway.
    Biosci Rep. 2019 Jul 1. pii: BSR20182270. doi: 10.1042/BSR20182270.
    Abstract    

    Abstract available

  39. MALMSTROM PU, Gardmark T, Sherif A, Strock V, et al
    Incidence, survival and mortality trends of bladder cancer in Sweden 1997-2016.
    Scand J Urol. 2019 Jul 2:1-7. doi: 10.1080/21681805.2019.1632380.
    Abstract    

    Abstract available

  40. YAKOVLEV PG, Klyushin DA, Vereshchako RI
    Bladder sparing surgery in high-grade bladder cancer.
    Exp Oncol. 2019;41:160-165.
    Abstract    

    Abstract available

  41. LORAS A, Martinez-Bisbal MC, Quintas G, Gil S, et al
    Urinary Metabolic Signatures Detect Recurrences in Non-Muscle Invasive Bladder Cancer.
    Cancers (Basel). 2019;11.
    Abstract    

    Abstract available

  42. HUAQI Y, Caipeng Q, Qiang W, Yiqing D, et al
    The role of SOX18 in bladder cancer and its underlying mechanism in mediating cellular functions.
    Life Sci. 2019 Jun 28:116614. doi: 10.1016/j.lfs.2019.116614.
    Abstract    

    Abstract available

  43. WANG W, Xu Z, Wang J, Chen R, et al
    LINC00978 promotes bladder cancer cell proliferation, migration and invasion by sponging miR4288.
    Mol Med Rep. 2019;20:1866-1872.
    Abstract    

    Abstract available

  44. ZHENG F, Wang M, Li Y, Huang C, et al
    CircNR3C1 inhibits proliferation of bladder cancer cells by sponging miR-27a-3p and downregulating cyclin D1 expression.
    Cancer Lett. 2019 Jun 27. pii: S0304-3835(19)30379.
    Abstract    

    Abstract available

  45. IWATA T, Kimura S, Abufaraj M, Janisch F, et al
    Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer.
    Urol Oncol. 2019 Jun 26. pii: S1078-1439(19)30219.
    Abstract    

    Abstract available

  46. DANIELS MJ, Barry E, Schoenberg M, Lamm DL, et al
    Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer.
    Urol Oncol. 2019 Jun 26. pii: S1078-1439(19)30218.
    Abstract    

    Abstract available

  47. ELBADAWY M, Usui T, Mori T, Tsunedomi R, et al
    Establishment of a novel experimental model for muscle-invasive bladder cancer by using dog bladder cancer organoid culture.
    Cancer Sci. 2019 Jun 29. doi: 10.1111/cas.14118.
    Abstract    

    Abstract available

  48. TSAI YS, Jou YC, Tsai HT, Cheong IS, et al
    Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer.
    Urol Oncol. 2019 Jun 25. pii: S1078-1439(19)30191.
    Abstract    

    Abstract available

  49. CHEN X, Wang P, Wang S, Li J, et al
    CIZ1 knockdown suppresses the proliferation of bladder cancer cells by inducing apoptosis.
    Gene. 2019 Jun 25:143946. doi: 10.1016/j.gene.2019.143946.
    Abstract    

    Abstract available

  50. LI F, Yang C, Zhang HB, Ma J, et al
    BET inhibitor JQ1 suppresses cell proliferation via inducing autophagy and activating LKB1/AMPK in bladder cancer cells.
    Cancer Med. 2019 Jun 28. doi: 10.1002/cam4.2385.
    Abstract    

    Abstract available

  51. RAKHSHAN A, Esmaeili MH, Kahaei MS, Taheri M, et al
    A Single Nucleotide Polymorphism in GAS5 lncRNA is Associated with Risk of Bladder Cancer in Iranian Population.
    Pathol Oncol Res. 2019 Jun 27. pii: 10.1007/s12253-019-00693.
    Abstract    

    Abstract available

  52. KRAFFT U, Tschirdewahn S, Hess J, Harke NN, et al
    STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer Patients.
    Pathol Oncol Res. 2019 Jun 27. pii: 10.1007/s12253-019-00689.
    Abstract    

    Abstract available

  53. CHIRIFE AM, Villasante N, Rojas Bilbao E, Casas G, et al
    Individual patient risk of progression of urinary bladder papillary tumors estimated from biomarkers at initial transurethral resection of bladder tumor.
    J Cancer Res Clin Oncol. 2019;145:1709-1718.
    Abstract    

    Abstract available

  54. XIAO J, Wang M, He W, Wang J, et al
    Does Postoperative Rehabilitation for Radical Cystectomy Call for Enhanced Recovery after Surgery? A Systematic Review and Meta-analysis.
    Curr Med Sci. 2019;39:99-110.
    Abstract    

    Abstract available

  55. HSU FS, Wu JT, Lin JY, Yang SP, et al
    Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  56. MUJUKIAN A, Innamaa A, Lippiatt J, Melson L, et al
    Extensive extramammary Paget's disease of the vulva involving the bladder postradical split skin graft reconstruction.
    BMJ Case Rep. 2019;12.
    Abstract    



  57. CHAN VSH, Chan DLH, Hui SY, Lam WWM, et al
    Occult extra-adrenal pheochromocytoma in the urinary bladder.
    BMJ Case Rep. 2019;12.
    Abstract    



  58. XU J, Hua X, Jin H, Zhu J, et al
    NFkappaB2 p52 stabilizes rhogdibeta mRNA by inhibiting AUF1 protein degradation via a miR-145/Sp1/USP8-dependent axis.
    Mol Carcinog. 2019;58:777-793.
    Abstract    

    Abstract available

  59. TAN TW, Nair R, Saad S, Thurairaja R, et al
    Safe transition from extracorporeal to intracorporeal urinary diversion following robot-assisted cystectomy: a recipe for reducing operative time, blood loss and complication rates.
    World J Urol. 2019;37:367-372.
    Abstract    

    Abstract available


  60. G9a Inhibition Has Antitumor Activity in Bladder Cancer.
    Cancer Discov. 2019 Jul 12. pii: 2159-8290.CD-RW2019.
    Abstract    

    Abstract available

  61. ZHUANG C, Ma Q, Zhuang C, Ye J, et al
    LncRNA GClnc1 promotes proliferation and invasion of bladder cancer through activation of MYC.
    FASEB J. 2019 Jul 12:fj201900078RR. doi: 10.1096/fj.201900078.
    Abstract    

    Abstract available

  62. REZAEI F, Tabatabaee HR, Rahmanian V, Mirahmadizadeh A, et al
    The Correlation Between Bladder Cancer and Obesity, Overweight, Physical Inactivity, and Tobacco Use: An Ecological Study in Asian Countries.
    Ann Glob Health. 2019;85.
    Abstract    

    Abstract available

  63. YAN T, Ye XX
    MicroRNA-328-3p inhibits the tumorigenesis of bladder cancer through targeting ITGA5 and inactivating PI3K/AKT pathway.
    Eur Rev Med Pharmacol Sci. 2019;23:5139-5148.
    Abstract    

    Abstract available

  64. DONG ZC, Zhang D, Zhang XX, Yao ZQ, et al
    MiR-155 affects proliferation and apoptosis of bladder cancer cells by regulating GSK-3beta/beta-catenin pathway.
    Eur Rev Med Pharmacol Sci. 2019;23:5682-5690.
    Abstract    

    Abstract available

  65. ALANEE S
    Pyeloduodenal fistula complicating neoadjuvant chemotherapy in a patient diagnosed with muscle invasive bladder cancer.
    Urol Case Rep. 2019;26:100931.
    Abstract    

    Abstract available

  66. GOEL S, Sinha RJ, Bhaskar V, Aeron R, et al
    Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade.
    Asian J Urol. 2019;6:222-229.
    Abstract    

    Abstract available

  67. RODRIGUEZ D, Goulart C, Pagliarone AC, Silva EP, et al
    In vitro Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant BCG Strain for Bladder Cancer Treatment.
    Front Immunol. 2019;10:1460.
    Abstract    

    Abstract available

  68. MENESES-GUTIERREZ CL, Hernandez-Damian J, Pedraza-Chaverri J, Guerrero-Legarreta I, et al
    Antioxidant Capacity and Cytotoxic Effects of Catechins and Resveratrol Oligomers Produced by Enzymatic Oxidation against T24 Human Urinary Bladder Cancer Cells.
    Antioxidants (Basel). 2019;8.
    Abstract    

    Abstract available

  69. WU J, Yu Y, Huang L, Li Z, et al
    Dairy Product Consumption and Bladder Cancer Risk: A Meta-Analysis.
    Nutr Cancer. 2019 Jul 11:1-9. doi: 10.1080/01635581.2019.1637909.
    Abstract    

    Abstract available

  70. CAPUTO JM, Moran G, Muller B, Keller AT, et al
    The Management of Newly-Diagnosed Non-muscle Invasive Bladder Cancer in Veterans Integrated Services Network 02 of the Veterans Health Administration.
    Mil Med. 2019 Jul 11. pii: 5531171. doi: 10.1093.
    Abstract    

    Abstract available

  71. SHAN G, Tang T, Xia Y, Qian HJ, et al
    MEG3 interacted with miR-494 to repress bladder cancer progression through targeting PTEN.
    J Cell Physiol. 2019 Jul 11. doi: 10.1002/jcp.29025.
    Abstract    

    Abstract available

  72. MERTEN R, Ott O, Haderlein M, Bertz S, et al
    Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2).
    Oncologist. 2019 Jul 10. pii: theoncologist.2018-0280.
    Abstract    

    Abstract available

  73. KIM TJ, Moon HW, Kang S, Yang J, et al
    Urovysion FISH Could Be Effective and Useful Method to Confirm the Identity of Cultured Circulating Tumor Cells from Bladder Cancer Patients.
    J Cancer. 2019;10:3259-3266.
    Abstract    

    Abstract available

  74. CHEN Z, Du Y, Liu X, Chen H, et al
    EZH2 inhibition suppresses bladder cancer cell growth and metastasis via the JAK2/STAT3 signaling pathway.
    Oncol Lett. 2019;18:907-915.
    Abstract    

    Abstract available

  75. YU Z, Xu Q, Wang G, Rowe M, et al
    DNA topoisomerase IIalpha and RAD21 cohesin complex component are predicted as potential therapeutic targets in bladder cancer.
    Oncol Lett. 2019;18:518-528.
    Abstract    

    Abstract available

  76. RAJA SA, Shah STA, Tariq A, Bibi N, et al
    Caveolin-1 and dynamin-2 overexpression is associated with the progression of bladder cancer.
    Oncol Lett. 2019;18:219-226.
    Abstract    

    Abstract available

  77. LUCCA I, Hofbauer SL, Haitel A, Susani M, et al
    Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria.
    Oncol Lett. 2019;18:57-62.
    Abstract    

    Abstract available

  78. LIU C, Ge M, Ma J, Zhang Y, et al
    Homeobox A10 promotes the proliferation and invasion of bladder cancer cells via regulation of matrix metalloproteinase-3.
    Oncol Lett. 2019;18:49-56.
    Abstract    

    Abstract available

  79. ALIFRANGIS C, McGovern U, Freeman A, Powles T, et al
    Molecular and histopathology directed therapy for advanced bladder cancer.
    Nat Rev Urol. 2019 Jul 9. pii: 10.1038/s41585-019-0208.
    Abstract    

    Abstract available


  80. Correction: Life and bladder cancer: protocol for a longitudinal and cross-sectional patient-reported outcomes study of Yorkshire (UK) patients.
    BMJ Open. 2019;9:e030850corr1.
    Abstract    



  81. RICHTER C, Marquardt S, Li F, Spitschak A, et al
    Rewiring E2F1 with classical NHEJ via APLF suppression promotes bladder cancer invasiveness.
    J Exp Clin Cancer Res. 2019;38:292.
    Abstract    

    Abstract available

  82. ISLAM A, Yang YT, Wu WH, Chueh PJ, et al
    Capsaicin attenuates cell migration via SIRT1 targeting and inhibition to enhance cortactin and beta-catenin acetylation in bladder cancer cells.
    Am J Cancer Res. 2019;9:1172-1182.
    Abstract    

    Abstract available

  83. CHAKRABORTY A, Dasari S, Long W, Mohan C, et al
    Urine protein biomarkers for the detection, surveillance, and treatment response prediction of bladder cancer.
    Am J Cancer Res. 2019;9:1104-1117.
    Abstract    

    Abstract available

  84. ALI A, Song YP, Mehta S, Mistry H, et al
    Palliative radiotherapy in bladder cancer - importance of patient selection: A retrospective multicenter study.
    Int J Radiat Oncol Biol Phys. 2019 Jul 5. pii: S0360-3016(19)33441.
    Abstract    

    Abstract available

  85. ZHANG WY, Wang HR, Hu H, Wang Q, et al
    [Clinical Features and Diagnosis of Encrusted Bladder Cancer].
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019;41:430-434.
    Abstract    

    Abstract available

  86. KAWADA T
    Risk assessment of bladder cancer: lifestyle and nutritional contribution.
    Urol Oncol. 2019 Jul 4. pii: S1078-1439(19)30222.
    Abstract    



  87. GROSSMAN HB, Bellmunt J, Black PC
    Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?
    Eur Urol Oncol. 2019 Jul 3. pii: S2588-9311(19)30077.
    Abstract    

    Abstract available

  88. XIAO KH, Teng K, Ye YL, Tan L, et al
    Kinesin family member C1 accelerates bladder cancer cell proliferation and induces epithelial-mesenchymal transition via the Akt/GSK3beta signaling.
    Cancer Sci. 2019 Jul 6. doi: 10.1111/cas.14126.
    Abstract    

    Abstract available

  89. BOERI L, Soligo M, Frank I, Boorjian SA, et al
    Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes.
    Eur Urol Oncol. 2019;2:390-396.
    Abstract    

    Abstract available

  90. LIPUNOVA N, Wesselius A, Cheng KK, van Schooten FJ, et al
    Genome-wide Association Study for Tumour Stage, Grade, Size, and Age at Diagnosis of Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2019;2:381-389.
    Abstract    

    Abstract available

  91. COLE AP, Ramaswamy A, Harmouch S, Fletcher SA, et al
    Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?
    Eur Urol Oncol. 2019;2:349-354.
    Abstract    

    Abstract available

  92. ASHIRU O, Esteso G, Garcia-Cuesta EM, Castellano E, et al
    BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine.
    Cancers (Basel). 2019;11.
    Abstract    

    Abstract available

  93. LEE J, Jeh SU, Koh DH, Chung DY, et al
    Probe-Based Confocal Laser Endomicroscopy During Transurethral Resection of Bladder Tumors Improves the Diagnostic Accuracy and Therapeutic Efficacy.
    Ann Surg Oncol. 2019;26:1158-1165.
    Abstract    

    Abstract available

  94. DAGLI R, Dadali M, Emir L, Bagbanci S, et al
    Comparison of Classic and Inguinal Obturator Nerve Blocks Applied for Preventing Adductor Muscle Contractions in Bladder Tumor Surgeries: A Prospective Randomized Trial.
    Urol J. 2019;16:62-66.
    Abstract    

    Abstract available

  95. DEVRIM T, Atac F, Altunkaya C, Ozbek A, et al
    Rare Plasmacytoid Urothelial Carcinoma of the Bladder: Two Case Reports.
    Urol J. 2019;16:86-88.
    Abstract    

    Abstract available

  96. HENSLEY PJ, Kyprianou N, Purdom MS, He D, et al
    Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy.
    Urol Oncol. 2019 Jul 17. pii: S1078-1439(19)30249.
    Abstract    

    Abstract available

  97. LI Q, Wang H, Peng H, Huang Q, et al
    MicroRNAs: Key Players in Bladder Cancer.
    Mol Diagn Ther. 2019 Jul 19. pii: 10.1007/s40291-019-00410.
    Abstract    

    Abstract available

  98. HUISMAN H
    Solid Science of AI Supporting Bladder Cancer CT Reading.
    Acad Radiol. 2019 Jul 17. pii: S1076-6332(19)30320.
    Abstract    



  99. MAI G, Chen L, Li R, Liu Q, et al
    Common Core Bacterial Biomarkers of Bladder Cancer Based on Multiple Datasets.
    Biomed Res Int. 2019;2019:4824909.
    Abstract    

    Abstract available

  100. TSUCHIYAMA K, Ito H, Seki M, Inai K, et al
    Advanced bladder cancer with malignant psoas syndrome: A case report with a focus on physical findings and complications.
    Urol Case Rep. 2019;26:100958.
    Abstract    

    Abstract available

  101. KIMURA Y, Honda M, Morizane S, Hikita K, et al
    Effect of Intravesical Bacilli Calmette-Guerin Therapy After Second Transurethral Resection in Stage Ta T1 High-Grade Bladder Cancer.
    Yonago Acta Med. 2019;62:191-197.
    Abstract    

    Abstract available

  102. JAMIL ML, Deebajah M, Sood A, Robinson K, et al
    Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guerin for patients with high-risk non-muscle invasive bladder cancer.
    BMJ Open. 2019;9:e028287.
    Abstract    

    Abstract available

  103. BUNCH B, Krishnan N, Greenspan RD, Ramakrishnan S, et al
    TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).
    Cell Cycle. 2019 Jul 18:1-12. doi: 10.1080/15384101.2019.1638693.
    Abstract    

    Abstract available

  104. ZHANG YP, Liu KL, Wang YX, Yang Z, et al
    Down-regulated RBM5 inhibits bladder cancer cell apoptosis by initiating an miR-432-5p/beta-catenin feedback loop.
    FASEB J. 2019 Jul 18:fj201900537R. doi: 10.1096/fj.201900537.
    Abstract    

    Abstract available

  105. AMPONSA VO, Shuman L, Ellis J, Wang E, et al
    Carcinogen-induced bladder cancer in the FVB mouse strain is associated with glandular differentiation and increased Cd274/Pdl-1 expression.
    Am J Clin Exp Urol. 2019;7:139-152.
    Abstract    

    Abstract available

  106. XIE X, Lin J, Zhong Y, Fu M, et al
    FGFR(3S249C) mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells.
    Exp Ther Med. 2019;18:1226-1234.
    Abstract    

    Abstract available

  107. DUENAS M, Perez-Figueroa A, Oliveira C, Suarez-Cabrera C, et al
    Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status.
    Sci Rep. 2019;9:10362.
    Abstract    

    Abstract available

  108. WANG Y, Li Z, Lin Q, Wei Y, et al
    Highly Sensitive Detection of Bladder Cancer-Related miRNA in Urine Using Time-Gated Luminescent Biochip.
    ACS Sens. 2019 Jul 17. doi: 10.1021/acssensors.9b00927.
    Abstract    

    Abstract available

  109. ZHANG S, Cao H, Ye L, Wen X, et al
    Cancer-associated methylated lncRNAs in patients with bladder cancer.
    Am J Transl Res. 2019;11:3790-3800.
    Abstract    

    Abstract available

  110. CASSELL A, Yunusa B, Jalloh M, Mbodji MM, et al
    Non-Muscle Invasive Bladder Cancer: A Review of the Current Trend in Africa.
    World J Oncol. 2019;10:123-131.
    Abstract    

    Abstract available

  111. GHANDOUR R, Singla N, Lotan Y
    Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer.
    Trends Cancer. 2019;5:426-439.
    Abstract    

    Abstract available

  112. HU X, Feng H, Huang H, Gu W, et al
    Downregulated Long Noncoding RNA PART1 Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer.
    Technol Cancer Res Treat. 2019;18:1533033819846638.
    Abstract    

    Abstract available

  113. WU D, Lin J, Zhu Y, Zhang H, et al
    Expression of Testis-Specific Gene Antigen 10 (TSGA10) is Associated with Apoptosis and Cell Migration in Bladder Cancer Cells and Tumor Stage and Overall Survival in Patients with Bladder Cancer.
    Med Sci Monit. 2019;25:5289-5298.
    Abstract    

    Abstract available

  114. LYU L, Xiang W, Zhu JY, Huang T, et al
    Integrative analysis of the lncRNA-associated ceRNA network reveals lncRNAs as potential prognostic biomarkers in human muscle-invasive bladder cancer.
    Cancer Manag Res. 2019;11:6061-6077.
    Abstract    

    Abstract available

  115. DUDDERIDGE T, Stockley J, Nabi G, Mom J, et al
    A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria-A Prospective Multicentre Performance Evaluation of ADXBLADDER.
    Eur Urol Oncol. 2019 Jul 12. pii: S2588-9311(19)30081.
    Abstract    

    Abstract available

  116. CHENG Y, Huang C, Mo Y, Wu W, et al
    Long non-coding RNA UCA1 regulates tumor growth by impairing let-7e-dependent HMGA2 repression in bladder cancer.
    Cancer Biomark. 2019 Jul 5. pii: CBM182296. doi: 10.3233/CBM-182296.
    Abstract    

    Abstract available

  117. LU M, Chen S, Zhou Q, Wang L, et al
    Predicting recurrence of nonmuscle-invasive bladder cancer (Ta-T1): A study based on 477 patients.
    Medicine (Baltimore). 2019;98:e16426.
    Abstract    

    Abstract available

  118. JIANG D, Zhang Y, Yang L, Lu W, et al
    Long noncoding RNA HCG22 suppresses proliferation and metastasis of bladder cancer cells by regulation of PTBP1.
    J Cell Physiol. 2019 Jul 15. doi: 10.1002/jcp.29090.
    Abstract    

    Abstract available

  119. SU S, Gu L, Ma X, Li H, et al
    Comparison of Laparoscopic and Robot-assisted Radical Cystectomy for Bladder Cancer: Perioperative and Oncologic Outcomes.
    Clin Genitourin Cancer. 2019 Jun 19. pii: S1558-7673(18)30605.
    Abstract    

    Abstract available

  120. MONDAL AM, Ma AH, Li G, Krawczyk E, et al
    Fidelity of a PDX-CR model for bladder cancer.
    Biochem Biophys Res Commun. 2019 Jul 11. pii: S0006-291X(19)31325.
    Abstract    

    Abstract available

  121. LLORENTE C, Guijarro A, Hernandez V, Fernandez-Conejo G, et al
    Effect of hospital volume on 90-day mortality after radical cystectomy for bladder cancer in Spain.
    World J Urol. 2019 Jul 13. pii: 10.1007/s00345-019-02874.
    Abstract    

    Abstract available

  122. DIANA M, Felipe-Sotelo M, Bond T
    Disinfection byproducts potentially responsible for the association between chlorinated drinking water and bladder cancer: A review.
    Water Res. 2019;162:492-504.
    Abstract    

    Abstract available

  123. YANG F, Zhou Q, Meng L, Xing N, et al
    IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype.
    Medicine (Baltimore). 2019;98:e16009.
    Abstract    

    Abstract available

  124. QIU S, Deng L, Liao X, Nie L, et al
    Tumor-associated macrophages promote bladder tumor growth through PI3K/AKT signal induced by collagen.
    Cancer Sci. 2019;110:2110-2118.
    Abstract    

    Abstract available

  125. HU SW, Wu CC, Chen KC, Ho CH, et al
    Modified U-Shaped ileal neobladder designed for facilitating neobladder-urethral anastomosis in extracorporeal reconstruction after robotic-assisted radical cystectomy.
    J Cancer Res Ther. 2019;15.
    Abstract    

    Abstract available

  126. ELSHARKAWI F, Elsabah M, Shabayek M, Khaled H, et al
    Urine and Serum Exosomes as Novel Biomarkers in Detection of Bladder Cancer.
    Asian Pac J Cancer Prev. 2019;20:2219-2224.
    Abstract    

    Abstract available

  127. TAN GH, Kuk C, Zlotta AR
    Are there differences among Bacillus Calmette-Guerin (BCG) strains regarding their clinical efficacy in the treatment of non-muscle invasive bladder cancer? The jury is still out but the answer is likely no.
    Can Urol Assoc J. 2019 Jul 23. pii: cuaj.5923. doi: 10.5489/cuaj.5923.
    Abstract    



  128. JIANG S, Wang J, Yang C, Tan R, et al
    Continuous culture of urine-derived bladder cancer cells for precision medicine.
    Protein Cell. 2019 Jul 25. pii: 10.1007/s13238-019-0649.
    Abstract    



  129. STEC R, Cierniak S, Lubas A, Brzoskowska U, et al
    Intensity of Nuclear Staining for Ki-67, p53 and Survivin as a New Prognostic Factor in Non-muscle Invasive Bladder Cancer.
    Pathol Oncol Res. 2019 Jun 19. pii: 10.1007/s12253-019-00678.
    Abstract    

    Abstract available

  130. CHEREMISIN D, Gavrilov P, Andropova P
    A case of renal tuberculosis following BCG therapy for bladder cancer.
    QJM. 2019 Jul 25. pii: 5538982. doi: 10.1093.
    Abstract    

    Abstract available

  131. PANDEY P, Siddiqui MH, Behari A, Kapoor VK, et al
    Jab1-siRNA Induces Cell Growth Inhibition and Cell Cycle Arrest in Gall Bladder Cancer Cells via Targeting Jab1 Signalosome.
    Anticancer Agents Med Chem. 2019 Jul 25. pii: ACAMC-EPUB-99966.
    Abstract    

    Abstract available

  132. TSAI TF, Lin JF, Lin YC, Chou KY, et al
    Cisplatin contributes to programmed death-ligand 1 (PD-L1) expression in bladder cancer through ERK1/2 - AP-1 signaling pathway.
    Biosci Rep. 2019 Jul 24. pii: BSR20190362. doi: 10.1042/BSR20190362.
    Abstract    

    Abstract available

  133. YANG Z, Fu B, Zhou L, Xu J, et al
    RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
    BMC Urol. 2019;19:69.
    Abstract    

    Abstract available

  134. KONECKI T, Kutwin P, Lowicki R, Juszczak AB, et al
    Hexaminolevulinate in the Management of Nonmuscle Invasive Bladder Cancer: A Meta-Analysis.
    Photobiomodul Photomed Laser Surg. 2019 Jul 24. doi: 10.1089/photob.2019.4634.
    Abstract    

    Abstract available

  135. GAO Y, Liu S, Guo Q, Zhang S, et al
    Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
    Int J Biol Sci. 2019;15:1488-1499.
    Abstract    

    Abstract available

  136. STARRETT GJ, Buck CB
    BK polyomavirus is a cause of bladder cancer.
    Curr Opin Virol. 2019;39:8-15.
    Abstract    

    Abstract available

  137. PAN S, Zhan Y, Chen X, Wu B, et al
    Identification of Biomarkers for Controlling Cancer Stem Cell Characteristics in Bladder Cancer by Network Analysis of Transcriptome Data Stemness Indices.
    Front Oncol. 2019;9:613.
    Abstract    

    Abstract available

  138. CHEN Z, Liu G, Hossain A, Danilova IG, et al
    A co-expression network for differentially expressed genes in bladder cancer and a risk score model for predicting survival.
    Hereditas. 2019;156:24.
    Abstract    

    Abstract available

  139. HAQUE W, Verma V, Aghazadeh M, Darcourt J, et al
    Short-term Mortality Associated with Definitive Chemoradiotherapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2019 Jul 2. pii: S1558-7673(19)30204.
    Abstract    

    Abstract available

  140. TONG Z, Sathe A, Ebner B, Qi P, et al
    Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer.
    J Exp Clin Cancer Res. 2019;38:322.
    Abstract    

    Abstract available

  141. SHAMALIRWA BB, Wembonyama O, Tidahy R, Mellas S, et al
    [Metastatic bladder metachrone to a kaposi sarcoma cancer at a therapeutic impasse: about a case].
    Pan Afr Med J. 2019;32:218.
    Abstract    

    Abstract available

  142. CHEN X
    MiR-101 acts as a novel bio-marker in the diagnosis of bladder carcinoma.
    Medicine (Baltimore). 2019;98:e16051.
    Abstract    

    Abstract available

  143. BOURAS E, Karakioulaki M, Bougioukas KI, Aivaliotis M, et al
    Gene promoter methylation and cancer: An umbrella review.
    Gene. 2019;710:333-340.
    Abstract    

    Abstract available

  144. FARAJ KS, Abdul-Muhsin HM, Navaratnam AK, Rose KM, et al
    Intracorporeal orthotopic neobladder formation: Why not to do it?
    Arch Esp Urol. 2019;72:318-325.
    Abstract    

    Abstract available

  145. GASTON R, Ramirez P
    Intracorporeal neobladder.
    Arch Esp Urol. 2019;72:309-317.
    Abstract    

    Abstract available

  146. MEDINA LG, Baccaglini W, Hernandez A, Rajarubendra N, et al
    Robotic intracorporeal ileal conduit: Technical aspects.
    Arch Esp Urol. 2019;72:299-308.
    Abstract    

    Abstract available

  147. GAYA JM, Vila-Reyes H, Gavrilov P, Territo A, et al
    Robotic radical cystectomy.
    Arch Esp Urol. 2019;72:293-298.
    Abstract    

    Abstract available

  148. DOTSON A, May A, Davaro F, Raza SJ, et al
    Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy.
    Int J Clin Oncol. 2019;24:706-711.
    Abstract    

    Abstract available

  149. VOM DORP F
    [Organ preservation in cancer of the upper urinary tract].
    Urologe A. 2019;58:22-24.
    Abstract    

    Abstract available

  150. CHENG L, Berney DM
    Annual review issue: Urologic pathology: a remarkable journey of innovation.
    Histopathology. 2019;74:3.
    Abstract    



  151. GUNLUSOY B, Bolat D, Degirmenci T
    Re: "Monopolar vs. bipolar transurethral resection for nonmuscle invasive bladder carcinoma: A post hoc analysis from a randomized controlled trial".
    Urol Oncol. 2019;37:177-178.
    Abstract    



  152. LUNNEY A, Haynes A, Sharma P
    Moderate or severe LUTS is associated with increased recurrence of non - muscle - invasive urothelial carcinoma of the bladder.
    Int Braz J Urol. 2019;45:306-314.
    Abstract    

    Abstract available

  153. CHIANG CH, Yeh CY, Chung JG, Chiang IT, et al
    Amentoflavone Induces Apoptosis and Reduces Expression of Anti-apoptotic and Metastasis-associated Proteins in Bladder Cancer.
    Anticancer Res. 2019;39:3641-3649.
    Abstract    

    Abstract available

  154. FILIPPOU P, Smith AB
    A new horizon for bladder preservation in muscle-invasive bladder cancer.
    BJU Int. 2019;124:184-185.
    Abstract    



  155. MARTINI A, Sfakianos JP, Renstrom-Koskela L, Mortezavi A, et al
    The Natural History of Untreated Muscle Invasive Bladder Cancer.
    BJU Int. 2019 Jul 16. doi: 10.1111/bju.14872.
    Abstract    

    Abstract available

  156. RAI BP, Bondad J, Vasdev N, Adshead J, et al
    Robotic versus open radical cystectomy for bladder cancer in adults.
    BJU Int. 2019 Jul 15. doi: 10.1111/bju.14870.
    Abstract    

    Abstract available

  157. ANNELS NE, Mansfield D, Arif M, Ballesteros-Merino C, et al
    Viral targeting of non-muscle invasive bladder cancer and priming of anti-tumour immunity following intravesical Coxsackievirus A21.
    Clin Cancer Res. 2019 Jul 4. pii: 1078-0432.CCR-18-4022.
    Abstract    

    Abstract available

  158. SADIGHIAN M, Porten S
    Gender differences in oncologic and functional outcomes in patients with bladder cancer undergoing radical cystectomy with urinary diversion.
    Curr Opin Urol. 2019 Jul 15. doi: 10.1097/MOU.0000000000000660.
    Abstract    

    Abstract available

  159. KETTUNEN K, Bostrom PJ, Lamminen T, Heinosalo T, et al
    Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells.
    Eur Urol. 2019 Jun 27. pii: S0302-2838(19)30501.
    Abstract    

    Abstract available

  160. PEDERZOLI F, Bandini M, Briganti A, Plimack ER, et al
    Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.
    Eur Urol. 2019 Jul 11. pii: S0302-2838(19)30522.
    Abstract    

    Abstract available

  161. COMPERAT E, Amin M, Reuter V
    Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.05.001: Two Decades of Wor
    Eur Urol. 2019 Jul 23. pii: S0302-2838(19)30541.
    Abstract    



  162. RIJNDERS M, van der Veldt AAM, Zuiverloon TCM, Grunberg K, et al
    PD-L1 Antibody Comparison in Urothelial Carcinoma.
    Eur Urol. 2019;75:538-540.
    Abstract    



  163. VAN DIJK N, Funt SA, Blank CU, Powles T, et al
    The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
    Eur Urol. 2019;75:435-444.
    Abstract    

    Abstract available

  164. STROGGILOS R, Mokou M, Latosinska A, Makridakis M, et al
    Proteome-based classification of Non-Muscle Invasive Bladder Cancer.
    Int J Cancer. 2019 Jul 8. doi: 10.1002/ijc.32556.
    Abstract    

    Abstract available

  165. BASSETT JK, Brinkman MT, Dugue PA, Ueland PM, et al
    Circulating concentrations of B group vitamins and urothelial cell carcinoma.
    Int J Cancer. 2019;144:1909-1917.
    Abstract    

    Abstract available

  166. MORAN JD, Kim HH, Li Z, Moreno CS, et al
    SOX4 regulates invasion of bladder cancer cells via repression of WNT5a.
    Int J Oncol. 2019 Jun 26. doi: 10.3892/ijo.2019.4832.
    Abstract    

    Abstract available

  167. YASUI M, Kawahara T, Takamoto D, Izumi K, et al
    Distribution of androgen receptor expression in the urinary bladder.
    Int J Urol. 2019;26:305-306.
    Abstract    



  168. TOIDE M, Yokoyama M, Fujiwara M, Kijima T, et al
    Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and partial cyst
    Int J Urol. 2019 Jul 8. doi: 10.1111/iju.14054.
    Abstract    



  169. KOBAYASHI T
    Editorial Comment from Dr Kobayashi to Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induc
    Int J Urol. 2019 Jul 21. doi: 10.1111/iju.14075.
    Abstract    



  170. OSAWA T, Wei JT, Abe T, Kako Y, et al
    Development of the Japanese version of the health-related quality of life questionnaire for bladder cancer patients using the Bladder Cancer Index: A pilot study.
    Int J Urol. 2019 Jul 16. doi: 10.1111/iju.14073.
    Abstract    



  171. XU R, Li H, Wu S, Qu J, et al
    MicroRNA-1246 regulates the radio-sensitizing effect of curcumin in bladder cancer cells via activating P53.
    Int Urol Nephrol. 2019 Jun 24. pii: 10.1007/s11255-019-02210.
    Abstract    

    Abstract available

  172. KUROIWA K, Inokuchi J, Nishiyama H, Kojima T, et al
    Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.
    J Urol. 2019 Jun 28:101097JU0000000000000422. doi: 10.1097/JU.0000000000000422.
    Abstract    

    Abstract available

  173. ATALA A
    Re: Mouse and Human Urothelial Cancer Organoids: A Tool for Bladder Cancer Research.
    J Urol. 2019 Jul 9:10109701JU000057698421354.
    Abstract    



  174. CHANG SS
    Re: Population-Based Assessment of Racial/Ethnic Differences in Utilization of Radical Cystectomy for Patients Diagnosed with Bladder Cancer.
    J Urol. 2019 Jul 9:10109701JU0000576988055492.
    Abstract    



  175. XUE Y, Tong L, LiuAnwei Liu F, Liu A, et al
    Tumorinfiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer.
    Oncol Rep. 2019 Jun 12. doi: 10.3892/or.2019.7196.
    Abstract    

    Abstract available

  176. TOSTIVINT V, Roumiguie M, Cabarrou B, Verhoest G, et al
    [Orthotopic neobladder reconstruction for bladder cancer: robotic-assisted versus open-radical cystectomy for perioperative outcomes, functional results and quality of life].
    Prog Urol. 2019 Jun 22. pii: S1166-7087(19)30115.
    Abstract    

    Abstract available

  177. TOBERT CM, Nepple KG, McDowell BD, Charlton ME, et al
    COMPLIANCE WITH AMERICAN UROLOGICAL ASSOCIATION GUIDELINES FOR NON-MUSCLE INVASIVE BLADDER CANCER REMAINS POOR: ASSESSING FACTORS ASSOCIATED WITH NON-COMPLIANCE AND SURVIVAL IN A RURAL STATE.
    Urology. 2019 Jun 25. pii: S0090-4295(19)30562.
    Abstract    

    Abstract available

  178. TRILLA-FUERTES L, Gamez-Pozo A, Prado-Vazquez G, Zapater-Moros A, et al
    Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities.
    BMC Cancer. 2019;19:636.
    Abstract    

    Abstract available

  179. ZHANG L, Wu B, Zha Z, Qu W, et al
    Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:716.
    Abstract    

    Abstract available

  180. LIU W, Woolbright BL, Pirani K, Didde R, et al
    Tumor M2-PK: A novel urine marker of bladder cancer.
    PLoS One. 2019;14:e0218737.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;